Moreover, the use of SGLT-2 inhibitors with a proven heart failure benefit—empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin—for the treatment of diabetes is recommended by The American Diabetes Association and The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines among diabetic patients with confirmed HF or at high risk of HF [19,20]. The gene discussed is SLC5A2; the disease is hydrops fetalis.